Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy

Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2

(2017) Yuchun Niu et al.   Molecular Cancer

FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer

(2017) Lingfeng He et al.   Molecular Oncology

The Role of Neoadjuvant Trials in Drug Development for Solid Tumors

(2016) S. A. Funt et al.   CLINICAL CANCER RESEARCH

Accumulation of RNA-dependent protein kinase (PKR) in the nuclei of lung cancer cells mediates radiation resistance

(2016) Chuncheng Hao et al.   Oncotarget

Flap endonuclease 1 silencing is associated with increasing the cisplatin sensitivity of SGC-7901 gastric cancer cells

(2015) CHUNHONG XIE et al.   Molecular Medicine Reports

The role of DNA repair pathways in cisplatin resistant lung cancer

(2014) Shane O’Grady et al.   CANCER TREATMENT REVIEWS

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

(2014) Matthew D Hellmann et al.   LANCET ONCOLOGY

Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy

(2014) Chunhua Xu et al.   LUNG CANCER

Flap Endonuclease 1

(2013) Lata Balakrishnan et al.   Annual Review of Biochemistry

The role of TDP1 and APTX in mitochondrial DNA repair

(2013) Martin Meagher et al.   BIOCHIMIE

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after Neoadjuvant Chemotherapy

(2013) William N. William et al.   Journal of Thoracic Oncology

Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC

(2013) Chengcheng Guo et al.   Journal of Thoracic Oncology

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

(2012) Apar Pataer et al.   Journal of Thoracic Oncology

Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non-Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy

(2011) F. Yang et al.   CANCER RESEARCH

Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways

(2011) Haizhen Zhong et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

New driver mutations in non-small-cell lung cancer

(2011) William Pao et al.   LANCET ONCOLOGY

Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity

(2010) Abujiang Pataer et al.   CANCER BIOLOGY & THERAPY

Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment

(2010) H. Dopeso et al.   CLINICAL CANCER RESEARCH

Prognostic Significance of RNA-Dependent Protein Kinase on Non-Small Cell Lung Cancer Patients

(2010) A. Pataer et al.   CLINICAL CANCER RESEARCH

Tyrosyl-DNA Phosphodiesterase 1 Targeting for Modulation of Camptothecin-Based Treatment

(2010) G. Beretta et al.   CURRENT MEDICINAL CHEMISTRY

Discovery of a Novel Function for Human Rad51

(2010) Jay M. Sage et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Down-Regulation of Rad51 Expression Overcomes Drug Resistance to Gemcitabine in Human Non-Small-Cell Lung Cancer Cells

(2010) M.-S. Tsai et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials

(2010) Wei-An Song et al.   Journal of Thoracic Oncology

A Novel Histopathological Evaluation Method Predicting the Outcome of Non-small Cell Lung Cancer Treated by Neoadjuvant Therapy: The Prognostic Importance of the Area of Residual Tumor

(2010) Yuki Yamane et al.   Journal of Thoracic Oncology

Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity

(2009) A. Choudhury et al.   MOLECULAR CANCER THERAPEUTICS

Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells

(2008) J.-C. Ko et al.   CARCINOGENESIS

Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells

(2008) J.-C. Ko et al.   MOLECULAR CANCER THERAPEUTICS